Brief: Sangamo Therapeutics Q2 EPS USD -0.08 Vs. IBES Estimate USD -0.13

Sangamo Therapeutics

07/08/2025 21:01

Overview

Sangamo Q2 revenue rises to $18.3 mln but missed analyst expectations, per LSEG data

Net loss of $0.08 per share beats analyst estimates, per LSEG data

Outlook

Company reiterates 2025 operating expenses guidance of $135 mln to $155 mln

Result Drivers

NEUROLOGY PIPELINE - Initiation of first clinical site for STAND study in chronic neuropathic pain marks entry into clinical-stage neurology

EQUITY OFFERING - Raised $21 mln in net proceeds from equity offering, contributing to financial activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$18.31 mln
$31.70 mln (5 Analysts)
Q2 EPS
Beat
-$0.08
-$0.13 (4 Analysts)
Q2 Net Income
-$19.99 mln
Q2 Adjusted Operating Expenses
$33 mln
Q2 Operating Expenses
$36.20 mln
Q2 Operating Income
-$17.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 73.5% above its August 6 closing price of $0.53

Press Release: ID:nGNXxkmCr

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)